U.S. District Court grants preliminary injunction, clears sale of Dr. Reddy's Allegra D24 tablet

Dr. Reddy's Laboratories announced today that on Friday, 28 January 2011, the U.S. District Court of New Jersey filed a Stipulation and Order lifting an earlier motion for preliminary injunction and clearing the sale of Dr. Reddy's generic product version of Allegra® D24 (fexofenadine hydrochloride / pseudoephedrine hydrochloride 180mg / 240mg extended release tablet), which was approved by the FDA on March 16, 2010.

In addition, plaintiff's sanofi-aventis and Albany Molecular Research have been required to post a security with the Court, an amount of USD 40 million towards the possibility that the injunction had been wrongfully granted. Having been excluded from launching the generic product since the June 2010 hearing, Dr. Reddy's intends to pursue an award of this security.

Source: Dr. Reddy's Laboratories Ltd


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.